Chemical Space of FLT3 Inhibitors as the Potential Anti-AML Drugs.

Chemical Space of FLT3 Inhibitors as the Potential Anti-AML Drugs. Recent Pat Anticancer Drug Discov. 2017 Jul 27;: Authors: Lan Q, Zhi Y, Heng H, Guo X, Liu H, Chen Y, Lu T, Lu S Abstract FLT3 is a member of receptor tyrosine kinase III family, expressed in normal bone marrow cells, early progenitor cells and hematopoietic stem cells. The aberrant expression and function of FLT3 are strongly related leukemia, especially acute myeloid leukemia. Its complex amino-acid residues mutations can induce ligand independent activation and downstream signaling transduction, leading to constant proliferation of hematological tumor cells with poor prognosis. Hence FLT3 serves as a promising target in AML chemotherapy. More recently, many small-molecule FLT3 kinase inhibitors are under study and several inhibitors have reached the advanced clinical trials for the treatment of leukemia. This review will focus on FLT3 inhibitors, which have entered clinical trials, and reported in numerous patents all over the world. PMID: 28748750 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research